5,5'-(Diazene-1,2-diyl)bis(2-hydroxybenzoic acid)

Catalog No. :
ACMGDI607
CAS No. :
15722-48-2
Molecular Formula :
C14H10N2O6
Molecular Weight :
302.24

IUPAC Name:(E)-5,5'-(diazene-1,2-diyl)bis(2-hydroxybenzoic acid)

5,5'-(Diazene-1,2-diyl)bis(2-hydroxybenzoic acid) structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg98%$160.00Login to see priceIn stockInquiry
250mg98%$271.00Login to see priceIn stockInquiry
1g98%$728.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name5,5'-(Diazene-1,2-diyl)bis(2-hydroxybenzoic acid)
IUPAC Name(E)-5,5'-(diazene-1,2-diyl)bis(2-hydroxybenzoic acid)
Molecular FormulaC14H10N2O6
Molecular Weight302.24
SMILESOC(C=C1)=C(C(O)=O)C=C1/N=N/C2=CC(C(O)=O)=C(O)C=C2
InChI KeyQQBDLJCYGRGAKP-FOCLMDBBSA-N
SynonymDTXSID8023391 | Salicylic acid, 5,5'-azodi- | Olsalazina | OLSALAZINE [INN] | 5-[(3-carboxy-4-hydroxyphenyl)diazenyl]-2-hydroxybenzoic acid | CHEBI:7770 | Rasal | 5,5'-(diazene-1,2-diyl)bis(2-hydroxybenzoic acid) | PD055722 | QQBDLJCYGRGAKP-UHFFFAOYSA-N |
CAS No.15722-48-2
PubChem CID22419

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H315-H319
Precautionary Statement(s)
P264-P280-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364

Synthetic Route by SureRoute

1. ACMGDI607 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACKXBI037 route compound structure diagram
    ACKXBI03789-57-6 In Stock
  2. Plus
  3. ACTUDH940 route compound structure diagram
    ACTUDH940616-76-2 In Stock
  4. Then
  5. ACMGDI607 route product structure diagram
    ACMGDI60715722-48-2 In Stock
Inquiry

2. ACMGDI607 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACMGDI607 route product structure diagram
    ACMGDI60715722-48-2 In Stock
Inquiry

Comments (0)